Company news

Verastem, Inc. news in 2025

Verastem, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

December 28, 2025

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

December 14, 2025

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

November 24, 2025

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

November 13, 2025

Verastem Oncology Announces Proposed Public Offering of Common Stock

November 12, 2025

Verastem Oncology to Present at Upcoming Investor Conferences

November 4, 2025

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

November 3, 2025

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

October 22, 2025

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

October 22, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

October 18, 2025

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

August 12, 2025

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

August 6, 2025

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

July 28, 2025

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

July 23, 2025

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

July 10, 2025

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

June 29, 2025

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

June 23, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

June 1, 2025

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 27, 2025

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 21, 2025

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 12, 2025

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 7, 2025

Verastem Oncology Announces $75 million Private Placement

April 24, 2025

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

April 22, 2025

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

March 24, 2025

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

March 19, 2025

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

February 19, 2025

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

January 28, 2025

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

January 22, 2025

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

January 14, 2025

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

January 13, 2025

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

January 12, 2025

Calls in 2025

Decks in 2025